Fig. 1
From: Integrated analysis of the voltage-gated potassium channel-associated gene KCNH2 across cancers
Differential expression of KCNH2 in tumour versus normal samples for 34 tumour types. GBM, glioblastoma multiforme; GBMLGG, glioma; LGG, brain lower grade glioma; UCEC, uterine corpus endometrial carcinoma; BRCA, breast invasive carcinoma; CESC, cervical squamous cell carcinoma and endocervical adenocarcinoma; LUAD, lung adenocarcinoma; ESCA, oesophageal carcinoma; STES, stomach and oesophageal carcinoma; KIRP, kidney renal papillary cell carcinoma; KIPAN, pan-kidney cohort (KICH + KIRC + KIRP); COAD, colon adenocarcinoma; COADREAD, colon adenocarcinoma/rectum adenocarcinoma oesophageal carcinoma; PRAD, prostate adenocarcinoma; STAD, stomach adenocarcinoma; HNSC, head and neck squamous cell carcinoma; KIRC, kidney renal clear cell carcinoma; LUSC, lung squamous cell carcinoma; LIHC, liver hepatocellular carcinoma; WT, high-risk Wilms tumour; SKCM, skin cutaneous melanoma; BLCA, bladder urothelial carcinoma; THCA, thyroid carcinoma; READ, rectum adenocarcinoma; OV, ovarian serous cystadenocarcinoma; PAAD, pancreatic adenocarcinoma; TGCT, testicular germ cell tumours; UCS, uterine carcinosarcoma; ALL, acute lymphoblastic leukaemia; LAML, acute myeloid leukaemia; PCPG, pheochromocytoma and paraganglioma; ACC, adrenocortical carcinoma; KICH, kidney chromophobe; CHOL, cholangiocarcinoma. *P < 0.05, **P < 0.01, ****P < 0.0001, − no significance